A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-L1-refractory melanoma

Ad Diab, Cara Haymaker, Wen-Jen Hsu, Marc Uemura, Ravi Mathi, Marcella James, James Geis, Mark Carroll, Suzanna Swann, Kathryn Lipton, Srinivas Chouduru, Rodabe Amaya, Sapna Patel, Hussain Tekw, Isabella Gitoua, Michael A. Davies, Willem Overwijk, Charlotte Barmakian, and Patrick Hwu

University of Texas MD Anderson Cancer Center, Houston, Texas; Idera Pharmaceuticals, Inc., Cambridge, MA and Eton, PA

BACKGROUND

Dendritic cell activation following IMO-2125 injection


Initial T-cell activation and cytokine release, detectable within 24 hrs of the first injection of IMO-2125


Tumor response to IMO-2125 + ipilimumab


Tumor imaging of patient with a complete response


CONCLUSIONS

The combination of IMO-2125 with ipilimumab is tolerable at all dose levels studied.

IMO-2125 exhibits substantial clinical activity in anti-PD-1 refractory melanoma. An additional PR of 1 year has been reported at 8mg.

Dendritic cells, evaluated within 24 hrs of the first IMO-2125 injection, are indicative for target expansion in the Phase II trial.

Further investigation of IMO-2125 with ipilimumab in anti-PD-1 refractory melanoma is warranted. The planned Phase II expansion is ongoing, and one post-RECIST response has been seen at 6mg.

References

• Long, JU 2016
• Yuan, COB 2017
• Yu, Antimicro Agents Chemo, 2016
• Wang, AACR 2016
• Long, SMR 2016
• Yu, Antimicro Agents Chemo, 2016
• Wang, AACR 2016

Idera sponsored by Idera Pharmaceuticals.

Corresponding author: Willem Overwijk, MD, PhD